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Recombinant human erythropoietin (rHuEPO, epoetin alfa) is a 165-amino acid glycoprotein that has been shown to initiate
response to hypoxia and is most widely known for its eﬃcacy in the treatment of a variety of anemias. A series of experiments were
conducted using rodent models to investigate the ability of systemically administered epoetin alfa to cross the blood-brain barrier
(BBB) and aﬀect the outcome of hypoxia and injury in the central nervous system. Results demonstrated that endogenous ery-
thropoietin (EPO) and EPO receptors are expressed around animal brain capillaries and that systemically administered epoetin alfa
crossed the BBB. The epoetin alfa group experienced signiﬁcantly reduced (P <0.01) tissue damage in an ischemic stroke model
when the study drug was administered 24 h before inducing stroke compared with control animals. Signiﬁcant protective eﬀects of
epoetin alfa persisted when epoetin alfa was administered up to 6 h poststroke (P <0.05). Similarly, epoetin alfa reduced trauma-
related brain injury when administered 24 h prior to and up to 6 h after blunt trauma when compared with the control group. The
volume of tissue necrosis was signiﬁcantly greater in control animals compared with those that received epoetin alfa (P <0.05). In
addition, these studies led to the postulate that epoetin alfa may also have an eﬀect on nervous system inﬂammation. This was
conﬁrmed using an experimental auto-immune encephalomyelitis model, where rats were shown to have signiﬁcantly delayed onset
(P <0.01) and reduced severity (P <0.05) of symptoms after treatment with epoetin alfa. Other studies demonstrated that epoetin
alfa had an eﬀect on the latency and severity of seizures and signiﬁcantly increased (P <0.0002) survival versus controls when mice
were exposed to the neurotoxin kainate (used to induce seizures). These ﬁndings suggest future potential therapeutic uses for
epoetin alfa beyond its anemia-related eﬀects.
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Recombinant human erythropoietin (rHuEPO, epoe-
tin alfa) is a 165-amino acid glycoprotein synthesised by
recombinant DNA technology. It has the same amino
acid sequence and biological eﬀects as endogenous ery-
thropoietin (EPO), the principal hormone responsible
for erythropoiesis [1]. Endogenous EPO is produced
primarily in the kidneys in response to hypoxia and cir-
culates through the bloodstream to the bone marrow
where it binds to its receptors on erythroid progenitor
cells, thereby stimulating red blood cell production. Any
decrease in kidney production of EPO results in a deﬁ-ciency of circulating red blood cells and subsequent
anemia.
For years it was believed that EPO was produced
exclusively in kidneys and fetal liver. However, recent
evidence indicates that EPO mRNA is expressed by
other tissues including adult liver (especially in times of
stress), brain, lung, testes and spleen. This suggests a
wider biologic role for EPO than previously recognized
[2–5].
In the central nervous system (CNS), EPO is expres-
sed by both neurons and glia and EPO expression
increases in response to hypoxia [6,7]. Expression of the
EPO receptor (EPO-R) has been detected in embryonic
mouse brains at levels comparable to those in adult
mouse hematopoietic tissue [8]. However, these levels
diminish with development and are not readily detectable
at birth [8]. These observations led to further studies,1359-6349/$ - see front matter # 2003 Elsevier Ltd. All rights reserved.
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demonstrating that both human and mouse EPO-R
genes are actively transcribed, not only in hematopoietic
tissue, but also in the developing embryonic brain, sug-
gesting that EPO-R may play an important role in the
development of select nonhematopoietic tissue [9].
Other studies showed that EPO and EPO-R are local-
ized in speciﬁc areas of embryonic, fetal and adult
brains of rats, monkeys and humans. Their persistence
in the mature brain is consistent with roles for EPO in
both CNS development and homeostasis [10–12]. Addi-
tionally, EPO and EPO-R mRNA have been detected in
biopsy material from the hippocampus, amygdala and
temporal cortex from humans as well as from various
brain regions of monkeys. In animal studies, experi-
ments with low levels of oxygen have resulted in ele-
vated levels of EPO mRNA [6,13]. Expression of EPO
and the EPO-R in the brain (particularly in such oxy-
gen-sensitive areas as the hippocampus and cerebral
cortex), regulation of their expression during fetal
development, and increased expression of EPO and
EPO-R under hypoxic conditions led to the hypothesis
that rHuEPO could act as a neurotrophic and neuro-
protective factor with possible therapeutic potential in
cases of brain damage due to hypoxia, ischemia or brain
hemorrhage [14].2. Neuroprotective function of EPO
Results of in vitro and in vivo studies have provided
evidence of a neuroprotective eﬀect of exogenous EPO.
Glutamate is an excitatory amino acid neurotransmitter
that mediates neuronal damage produced by hypoxia/
ischemia [5]. In vitro, EPO had been shown to protect
cultured rat hippocampal and cerebral cortical neurons
from glutamate toxicity [7,15,16]. It has also been
shown that EPO protects neuronal cultures from nitric-
oxide-induced death [16], rescues neuroblastoma cells
from hypoxia-induced apoptosis [17], and prevents the
death of cultured hippocampal neurons from newborn
rats when administered at the onset of hypoxia [18].
In vivo, EPO infusion into the cerebroventricles of
stroke-prone spontaneously hypertensive rats has been
shown to ameliorate ischemia-induced place-navigation
disability, cortical infarction, and thalamic degeneration
[19]. In a gerbil model of global cerebral ischemia, infu-
sion of EPO into the lateral ventricles prevented ischemia-
induced learning disabilities and rescued hippocampal
neurons from lethal ischemic damage [16]. Also, intraven-
tricular injection of recombinant mouse EPO resulted in a
signiﬁcant reduction in infarction volume in mice with
induced cerebral ischemia [7].
These observations set the stage for investigation of
the possible therapeutic eﬀects of EPO in CNS dis-
orders. Direct delivery of EPO into the CNS intrathe-
cally or via the intracerebroventricular system had beenshown to be neuroprotective in stroke models, but this
route of treatment is clinically impractical. Systemic
delivery to achieve CNS eﬀects was not considered at
that time, since it had always been assumed that large
molecules such as EPO could not cross the blood-brain
barrier (BBB). However, in a preclinical study char-
acterising the human BBB transferring receptor, cova-
lent coupling of a neuropharmaceutical with a brain
transport vector resulted in transportation across the
BBB [20]. Speciﬁc vectorial movement of macro-
molecules across the BBB begins by binding of the
macromolecule to receptors on the luminal surface of
endothelial cells. This initiates endocytosis and sub-
sequent translocation of the macromolecule across the
BBB [21]. In other studies, aluminum enhanced the
permeability of the BBB to certain hormones, the
greatest eﬀect being seen with thyroxine, which crosses
the BBB by carrier-mediated transport [22].
Against this background, a series of studies using
rodent models was initiated by Brines and colleagues to
investigate the expression of EPO and EPO-R in normal
brain tissue and the ability of a commercially available
rHuEPO (epoetin alfa) to cross the BBB [23,24]. Subse-
quently, four additional rodent-model studies were
conducted in which epoetin alfa was administered sys-
temically to assess its eﬀect on neuroprotection in focal
ischemic stroke, reduction of blunt trauma injury, reduc-
tion of the clinical severity of neurologic inﬂammation
and the latency and severity of seizures.
2.1. Erythropoietin and its receptor in the normal brain
The ﬁrst study investigated the expression pattern of
EPO and EPO-R in the brain [23,24]. Human, mouse
and rat tissues were stained using polyclonal antibodies
for immunohistochemical staining. The most intense
immunoreactivity for EPO-R was found in the frontal
cortex and hippocampus (Fig. 1). Speciﬁcally, EPO-R
was expressed to a large extent in many medium and
large neurons (wherein it was localized to the somata
and proximal dendrites), as well as capillaries, particu-
larly within white matter. High-power microscopic
examination revealed that capillaries were enveloped by
numerous EPO-R immunopositive processes derived
from nearby astrocytes. Transmission electron micro-
scopy conﬁrmed that the predominant EPO-R immu-
noreactivity was located in astrocyte foot processes
surrounding capillaries and was also present within or
on the surface of endothelial cells. There was no sig-
niﬁcant expression of EPO-R in larger vessels and most
astroglia.
2.2. Epoetin alfa crossed the BBB
The previous study demonstrated high expression of
capillary EPO-R at the BBB, suggesting that epoetin30 A. Cerami et al. / EJC Supplements Vol 2 No. 2 (2004) 29–35
alfa administered to the systemic circulation was
directly transported into the CNS. To conﬁrm these
observations, biotinylated epoetin alfa was injected
intraperitoneally (i.p.) into mice, and using the strepta-
vidin-peroxidase methodology, epoetin alfa was visua-
lized in brain sections at 5 and 17 h after injection
[23,24]. These time points were chosen based on the
pharmacokinetics of a single 5000-IU/kg epoetin dose
given i.p., where peak activity occurred at 5 h and serum
levels decreased to <1% of the peak concentration after
17 h.
After 5 h, biotinylated epoetin alfa was detected
around capillaries and extended into brain parenchyma.
When excess unlabelled epoetin alfa was injected toge-
ther with the labelled epoetin alfa, there was little or no
reactivity around capillaries (consistent with a speciﬁc
and saturable transport mechanism) (Fig. 2). After 17 h,
no labelled epoetin alfa was detected around capillaries
but, rather, was scattered around neurons. Separately,
signiﬁcant levels of labelled epoetin alfa were detected in
cerebrospinal ﬂuid obtained from cisterna magna of
male rats. These ﬁndings strongly suggest activetranslocation of epoetin alfa across the BBB that
speciﬁcally targets neurons.
2.3. Systemically administered epoetin alfa is
neuroprotective against focal ischemic stroke
The next study was designed to determine whether
epoetin alfa has protective eﬀects against focal ischemic
stroke [23,24]. Stroke was induced in male rats by per-
manently occluding the middle cerebral and right car-
otid arteries and then occluding the left carotid artery
for 1 h. (This procedure produces a penumbra {area at
risk} comprising an initially small necrotic core and a
large surrounding volume of potentially viable neurons
within the right frontal cortex. Ischemia, if untreated,
triggers apoptosis of susceptible neurons within the
penumbra over time.) Epoetin alfa, 250–5000 IU/kg,
was injected i.p. 24 h before occlusion of the left carotid
artery; simultaneously with occlusion; or 3, 6 or 9 h
after occlusion. A control group of animals was injected
with saline at the same time points.
After 24 h, brain tissue was harvested and living tissue
was distinguished from dead tissue using computerized
volumetric analysis of triphenyltetrazolium reduction.
Rats receiving epoetin alfa 24 h before and up to 3 h
after occlusion exhibited signiﬁcantly less damaged tis-
sue than did controls (P <0.01). Although the protec-
tive eﬀect diminished with time, after 6 h, signiﬁcant
protection was still detected (P <0.05). There was no
protection observed when epoetin alfa was given 9 h
after occlusion (Fig. 3). The lowest dose that oﬀered
protection was 450 IU/kg. This window of protection
was attributed to the ability of epoetin alfa to induce
protective genes in potentially viable cells within the
ischemic penumbra before they underwent apoptosis.
2.4. Epoetin alfa reduced injury by blunt-force trauma
Mechanical insult of the brain can result in ischemic,
inﬂammatory and excitotoxic injury, as well as cavitary
lesions. The potential role of epoetin alfa in reducing
traumatic injury created by blunt force to the brain was
investigated using rodent models [23,24]. A calibrated
piston was used to eﬀect a blow to the intact calvaria of
the frontal cortex of anesthetized animals. Epoetin alfa
was injected i.p. at a dose of 5000 IU/kg. Injections were
given at 24 h before the blow or at 0, 3 or 6 h after the
blow, and the doses were continued for 4 days. Ten days
after the blow, brains were harvested, sectioned and
stained for analysis.
There was less cavitary injury in brains from animals
who received epoetin alfa 24 h prior to and up to 6 h
after assault compared with the control group of animals
who did not receive epoetin alfa. Quantitative analysis
indicated a greater protective eﬀect in the epoetin alfa
group. The volume of necrosis was signiﬁcantly greaterFig. 2. Observations of biotinylated epoetin alfa activity after intra-
peritoneal injection into mice in brain sections at 5 h (panels A and B),
and after combination with 100 times excess of unlabeled epoetin alfa
(panel C). Reprinted with permission [23,24].Fig. 1. EPO-R immunoreactivity within the astrocyte foot processes
surrounding the capillaries (asterisks), and on the surface of endothe-
lial cells (arrows) in brain tissue. Reprinted with permission [23,24].A. Cerami et al. / EJC Supplements Vol 2 No. 2 (2004) 29–35 31
in the control animals than in the group that received
epoetin alfa (P <0.05) (Fig. 4). Additionally, in the
control animals, the region immediately surrounding the
necrotic core contained a large population of mono-
nuclear inﬂammatory cells, whereas in the epoetin-alfa-
treated animals, this region showed markedly reduced
inﬂammatory inﬁltrate, suggesting an immunomodula-
tory role for epoetin alfa.
2.5. Epoetin alfa reduced the clinical severity of
experimental encephalomyelitis
The observation that epoetin alfa treatment reduces
inﬂammatory inﬁltrate after trauma led to the postulate
that epoetin alfa might reduce nervous system inﬂam-
mation caused by other pathologic processes.
A rat model of experimental autoimmune encephalo-
myelitis was created to test this hypothesis [23,24].
Experimental autoimmune encephalomyelitis was
induced in female Lewis rats by immunisation withguinea pig myelin basic protein and complete Freund
adjuvant. Immunization induced clinical symptoms
after 10 days, and severe paralysis was observed after
day 12. Three days after immunization, two groups of
rats received either epoetin alfa (5000 IU/kg) or saline,
administered daily, with injections continuing for 15
subsequent days. Epoetin alfa signiﬁcantly delayed the
onset and reduced the severity of experimental auto-
immune encephalomyelitis symptoms compared with
controls (P <0.01 and P <0.05, respectively) (Fig. 5).
No rebound of symptoms occurred 3 weeks after termi-
nation of epoetin alfa therapy, in contrast to the occur-
rence of rebound that has been noted following
discontinuation of treatment in groups receiving other
therapies, such as glucocorticoids or interferon-beta
[25]. Whether the eﬀect of epoetin alfa in this model wasFig. 3. Eﬀect of systematic administration of epoetin alfa on infarct volume after cerebral occlusion in the rat at 24 h before occlusion, 6 h after
occlusion and 9 h after occlusion. Reprinted with permission [23,24].Fig. 4. Protective eﬀect of epoetin alfa administered 24 h before blunt-
force injury to the frontal cortex. Reprinted with permission [23,24].Fig. 5. Epoetin alfa signiﬁcantly delayed the onset and reduced the
severity of experimental autoimmune encephalomyelitis symptoms.
Reprinted with permission [23,24].32 A. Cerami et al. / EJC Supplements Vol 2 No. 2 (2004) 29–35
on the inﬂammatory system or immune system, or both,
is as yet unknown.
2.6. Eﬀects of epoetin alfa on latency and severity of
seizures induced by kainate
Excitotoxicity accompanies many diﬀerent forms of
brain injury [26], and it was postulated that epoetin alfa
might reduce such toxicity. A mouse model was
designed to test this hypothesis by examining the eﬀects
of epoetin alfa on toxicity caused by kainate, a gluta-
mate analogue whose toxicity generally results in sei-
zures [23,24]. First, the relationship among systematic
doses of kainate, its toxicity and the latency and severity
of seizures were determined. It was discovered that
when kainate was administered at the median eﬀective
dose (ED50) of approximately 20 mg/kg, death caused
by status epilepticus occurred some 18 min later.
As in previous experiments conducted in mouse
models, epoetin alfa was administered 24 h before the
administration of kainate. Mice receiving epoetin alfa
had delayed onset of status epilepticus and reduced
motor involvement compared with control mice. Mor-
tality was also reduced by approximately 45% (Fig. 6).
In the epoetin alfa group, mean survival time increased
signiﬁcantly compared with the control group (25.8 min
versus 18.2 min, P <0.0002). At doses below ED50 of 20
mg/kg, kainate produces behavioral seizures rather
than status epilepticus. The seizure activity induced by
this amount of kainate was signiﬁcantly reduced by
administration of epoetin alfa 24 h earlier. However,
epoetin alfa administered 30 min before or after kainate
exposure oﬀered no protective eﬀect from seizure activ-
ity. The seizure prevention of a single dose of epoetin
alfa at 5000 IU/kg lasted for at least 3 days, unlike
conventional antiepileptic agents, which requirecontinued administration after terminating seizure epi-
sodes to be eﬀective (Fig. 6). Epoetin alfa apparently
has a mode of action on seizure activity diﬀerent from
that of conventional anti-epileptic drugs.
2.7. Eﬀects of epoetin alfa on spinal cord ischemic injury
Erythropoietin and its receptor are expressed by
human neuronal and glial cells in the fetal spinal cord
[17]. These observations have led to several experi-
mental studies investigating whether epoetin alfa exerts
a neuroprotective eﬀect in spinal cord ischemia similar
to that exerted in the ischemic brain.
In an in vitro study, application of rHuEPO protected
fetal rat spinal motoneurons from apoptosis induced by
brain-derived neurotrophic factor deprivation or kainic
acid exposure [27]. To expand these results and those
obtained in the studies of Brines and his colleagues
[23,24], the possible neuroprotective and ameliorating
eﬀects of epoetin alfa were investigated in an experi-
mental transient global spinal cord ischemia model in
rabbits [28]. Spinal cord ischemia was produced by
occlusion of the abdominal aorta for 20 min. Saline or
epoetin alfa (350, 800 or 1000 IU/kg) was administered
intravenously immediately after the onset of reperfu-
sion. Epoetin alfa–treated animals, compared with
those given saline, exhibited better neurologic function
after 1 h of reperfusion. Neurologic status in all epoetin
alfa–treated animals continued to improve over the next
48 h, whereas saline-treated animals showed no
improvement (diﬀerence, P <0.05). Histologic exami-
nation of the spinal cord indicated widespread motor
neuron injury and a prominent inﬂammatory inﬁltrate
in the saline-treated but not in epoetin alfa–treated ani-
mals. This ﬁnding conﬁrmed the neuroprotective eﬀects
of epoetin alfa on spinal motoneurons against ischemic
insult. Moreover, terminal deoxynucleotidyltransferase-
mediated dUTP nick end-labeling (TUNEL) showed
many positive large motor neurons in the ventral gray
matter of control animals but only rare reaction product
in the gray matter of epoetin alfa–treated animals—a
ﬁnding that strongly supports an apoptosis-blocking
eﬀect of epoetin alfa in this class of neurons. These
ﬁndings suggest that epoetin alfa has both an acute and
a delayed beneﬁcial eﬀect on ischemic spinal cord injury
and acts through multiple mechanisms.3. Mechanisms and clinical implications of EPO
neuroprotection
It is well established that normalizing hemoglobin and
hematocrit levels with rHuEPO in uremic patients and
those with cancer- or treatment-related anemia can
maintain or improve quality of life and possibly also
cognitive function [29–34]. Additionally, results of inFig. 6. Epoetin alfa delays and lessens kainate-induced seizure.
Reprinted with permission [23,24].A. Cerami et al. / EJC Supplements Vol 2 No. 2 (2004) 29–35 33
vitro and in vivo studies indicate that rHuEPO may also
provide neuroprotective beneﬁts independent of its
hematologic eﬀects. A number of mechanisms have
been proposed for the neuroprotective eﬀects of
rHuEPO including repression of apoptosis either by
maintenance of Bcl-2 or Bcl-xl expression, as occurs
with erythroid precursor cells [5] or by inactivation of
caspases [35,36] via an EPO-induced increase in intracel-
lular calcium. Calcium inﬂux into neuronal cells leads, in
turn, to a sustained increase in neuronal nitric acid, which
inhibits caspase function [36]. Erythropoietin may also
provide neuroprotection by inhibiting glutamate release,
increasing glutamate uptake, or desensitizing glutamate
receptors. It is also possible that EPO upregulates
enzymes that scavenge oxygen radicals [5] or reduces
inﬂammation at the site of injury either directly via inhi-
bition of a member of the inﬂammatory cascade (e.g.
caspase) or indirectly by prevention of apoptosis [27].
The observed neuroprotective eﬀects of epoetin alfa in
several diﬀerent models of neuronal injury suggested
target CNS diseases/disorders that might beneﬁt from
such therapy. For example, in the model of ischemic
stroke [23,24], administration of epoetin alfa prevented
apoptosis of neurons within the ischemic penumbra and
decreased the infarct volume. In the clinical setting, such
an eﬀect in ischemic-stroke patients could translate into
less extensive injury and preservation of function (e.g.
speech, motor). In two other models of CNS injury, e.g.
blunt trauma [23,24] and spinal cord injury [28], epoetin
alfa attenuated neuronal injury and also markedly
reduced the inﬂammatory inﬁltrate. The anti-inﬂamma-
tory eﬀect is especially noteworthy, as both forms of
injury are characterized by intense inﬂammation, which
can have dire clinical consequences. In patients experi-
encing such injury, much of the neurological dysfunction
occurs as a result of disruption of the white matter
(ascending and descending long tracts), particularly
because of reactive inﬂammation-driven oligodendrocyte
apoptosis [37]. Epoetin alfa therapy also ameliorated the
latency and severity of kainate-induced seizures—a
model of temporal lobe epilepsy [23,24].
Based on its multiple actions, other target diseases/
disorders for which epoetin alfa therapy may aﬀord a
potential beneﬁt are amyotrophic lateral sclerosis
(ALS), Alzheimer’s disease and Parkinson’s disease.
Some known contributors to neuronal damage in these
diseases that could possibly be modulated by epoetin
alfa include excitotoxic damage and oxidative stress in
ALS, oxidative stress, free radical damage, glutamate-
related toxicity in Parkinson’s disease and glutamate-
mediated toxicity in Alzheimer’s disease [38].
Given the encouraging results obtained in animal
models, several clinical studies of the neuroprotective
eﬀects of rHuEPO are ongoing or under consideration.
In a pilot study conducted in Germany (the Go¨ttingen
EPO-Stroke Trial), 40 ischemic stroke patients weregiven intravenous injections of saline (control group,
n=20) or rHuEPO (n=20) within 5 h of onset of
symptoms [39]. The cerebrospinal ﬂuid EPO level
increased to 60–100 times that of the control group of
patients, demonstrating that intravenously administered
EPO reaches the brain. The treated patients subse-
quently had earlier as well as greater improvement in
follow-up and outcome scores. They also tended to have
smaller areas of damaged brain tissue, as measured by
MRI, 1 month after their strokes. In view of these
encouraging results, the study has been expanded into a
multicenter trial including four centers. In another
ongoing trial being conducted at eight centers, the eﬀect
of epoetin alfa on neurodegeneration is being assessed
in double-blind fashion in schizophrenic patients
receiving rHuEPO in addition to their symptomatic
neuroleptic medication [40].4. Conclusions
It has been demonstrated that EPO-R is expressed in
other cells besides erythroid progenitors and that epoe-
tin alfa may have signiﬁcant eﬀects on disease states
other than anemia. It was postulated that the drug has a
potential for treatment of CNS disorders, and the stud-
ies described were designed initially to examine whether
peripherally injected epoetin alfa could cross the BBB.
These experiments showed that peripherally injected
epoetin alfa crossed the BBB and protected brain tissue
from a variety of insults. The presence of EPO-R on brain
capillaries suggests speciﬁc translocation of EPO; how-
ever, the underlying biochemical mechanism for neuro-
protection requires further investigation.
The results of the rodent-model studies suggest that
epoetin alfa may be eﬀective as a therapy in various
CNS-speciﬁc illnesses such as ischemic stroke, epilepsy,
Parkinson’s disease, Alzheimer’s disease and amyo-
tropic lateral sclerosis. Further study of future clinical
uses is warranted.Acknowledgements
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